Straits Times Index
3,338.56 -10.31 (-0.31%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.27 (-0.30%) Nasdaq
16,828.67 +93.67 (+0.56%) Bitcoin USD
68,775.82 -330.98 (-0.48%) CMC Crypto 200
1,443.40 -3.75 (-0.26%)
Bavarian Nordic A/S (BVNRY)
| Previous close | 8.93 |
| Open | 9.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 8.92 - 9.00 |
| 52-week range | 5.95 - 10.65 |
| Volume | |
| Avg. volume | 3,797 |
| Market cap | 2.109B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | 14.62 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Mar 2020 |
| 1y target est | N/A |
- GlobeNewswire
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox disease in adults 18 years of age and older. The liquid-frozen formulation of JYNNEOS® was approved by the FDA in September 2019. It remains the only approved mpox vaccine anywhere in the world and the on
- GlobeNewswire
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
African trial could potentially support licensure of mpox vaccine in endemic countries and expansion of current regulatory approvals to include childrenCEPI has awarded USD 6.5 million in funding to support the Phase 2 clinical trial which is projected to start later in 2024 COPENHAGEN, Denmark / OSLO, Norway, May 30, 2024 – Bavarian Nordic A/S (OMX: BAVA) and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced a partnership to advance the development of Bavarian Nordic’s
- GlobeNewswire
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, May 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 187,020 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 18,702 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital incr
